Connor, Clark & Lunn Investment Management (CC&L)
RXDX

Connor, Clark & Lunn Investment Management (CC&L)’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RXDX Stock Details RXDX Fund Activity
Quarter Market Value Status Shares Shares
Change % 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,827
Closed -$411K – 1570
2023
Q1 		$411K Sell
3,827
-8,947
-70% -$960K ﹤0.01% 937
2022
Q4 		$1.41M Buy
+12,774
New +$1.41M 0.01% 621